Introduction: Glucometry is widely used to confirm or exclude hypoglycemia in patients with suggestive clinical findings. Nonglucose sugars may be detected by certain types of glucometers, causing false elevation of the glucometer analysis of the blood sugar. Since these other sugars are not functionally glucose and may even induce excess insulin release, clinical hypoglycemia may be missed.
INTRODUCTION
Portable point-of-care glucometer devices are often utilized to measure blood glucose in hospital settings. Portable bedside glucometers utilize enzymatic assays to provide a rapid measurement of capillary blood glucose, allowing for timely clinical decisions. While the accuracy of bedside glucometers has been extensively evaluated, false elevation of glucose measurements may occur when nonglucose sugars are present in the blood, such as galactose and maltose. Sugars may be exogenously introduced into the bloodstream for a variety of reasons, e.g., the absorption of icodextrin, a glucose polymer, which occurs while it is used in the dialysate solution for peritoneal dialysis. Accordingly, the US Food and Drug Administration issue a safety warning advising caution when using certain portable point-of-care monitors with patients receiving parenteral products containing maltose or galactose, and for oral xylose [1] . While false elevation of glucometry measurements have been reported in the aforementioned circumstances, it is not known to occur following the oral administration of maltose or its polymer, maltodextrin. We report a case of unrecognized fatal hypoglycemia in the setting of falsely elevated glucometer glucose concentration likely due to maltodextrin contained in enteral nutrition.
CASE REPORT
A 79 year-old-man with multiple medical problems, including insulin-dependent diabetes mellitus, was admitted to the hospital Unrecognized Hypoglycemia Due to Maltodextrin Interference with Bedside Glucometry for presumed sepsis. His medications prior to admission included furosemide 20 mg once a day, losartan 50 mg once a day, escitalopram 10 mg once every day, omeprazole 20 mg every day, lactobacillus, and potassium chloride 20 mEq once a day. In addition to these medications, the patient also received vancomycin, cefepime, amikacin, voriconazole, and both regular insulin and glargine insulin during his inpatient stay. On hospital day 3 he was started on enteral feeds containing maltodextrin (Peptamen, Nestle Nutrition, Vevey, Switzerland) at 50 ml/hr (1200 ml/day) by nasogastric tube. A routine evening (21:41) glucometer glucose concentration was 25.6 mmol/L (461 mg/dL) as measured by the Roche Accu-chek Advantage portable glucometer, which utilizes the glucose dehydrogenase enzyme with pyrroloquinolinequinone (GDH-PQQ). Subsequently, sliding scale insulin was administered (24 units insulin glargine subcutaneous and 10 units regular insulin subcutaneous) for this elevated reading. The next morning (05:51) a glucometer measurement was 11.1 mmol/L (200 mg/dL), and routine morning serum labs were sent simultaneously. The nursing notes indicated that the patient slept through the finger stick glucose check and blood draw. Approximately 1 hour later, the chemistry lab reported serum glucose of less than 1.11 mmol/L (Ͻ20 mg/dL). Intravenous glucose did not provide improvement, and the patient subsequently expired. Review of the patient's glucometer glucose concentrations compared to laboratory glucose concentrations revealed a persistently elevated reading with discrepancy between the serum and bedside values (Figure 1) .
DISCUSSION
Point-of-care glucometers use enzymatic assays to measure glucose concentrations. Several different enzymes are utilized by the various commercial glucometers, including glucose dehydrogenase, glucose oxidase, and hexose kinase. Analyzers using the glucose dehydrogenase system can be further subdivided based on cofactor utilized to catalyze the reaction: either nicotinamide adenine dinucleotide (GDH-NAD ϩ ) or pyrroloquinolinequinone (GDH-PQQ). Interference with glucose measurement has been reported to occur most commonly on analyzers using the GDH-PQQ enzyme [2] .
Neonates with galactosemia who consequently had elevated serum galactose levels were found to have falsely elevated glucose concentrations detected on point-of-care analyzers that used glucose dehydrogenase enzymes [3] . In a subsequent study on whole blood, the error did not occur with analyzers that measured glucose by using hexose kinase enzymes or those that used glucose oxidase enzymes [2] . Diabetic patients using icodextrin containing peritoneal dialysis fluid have had falsely elevated glucose readings [4] [5] [6] Icodextrin, a polymer of glucose, is used in peritoneal dialysis as an osmotic agent to facilitate fluid movement across membranes. When used for this purpose, icodextrin may be absorbed by the lymphatic system, and then subsequently hydrolyzed to glucose oligomers such as maltose, maltriose and maltotetraose [4] . When in vitro blood samples spiked with icodextrin metabolites are analyzed on point-of-care glucometers, the false glucose elevation is reproduced [2, 4, 7, 8] . This most consistently occurs on the GDH-PQQ analyzers, though in one study, interference was also found in a glucose oxidase glucometer [7] . Similar situations of falsely elevated glucose have occurred in patients receiving other maltose containing therapy. Recently, a patient receiving intravenous human immunoglobin (Octagam, Octapharma AG, Lachen, Switzerland), which contains maltose, had falsely elevated glucose values measured by a portable glucometer (glucose dehydrogenase), consequently was placed on high-dose insulin, and developed profound hypoglycemia [9] . Though the exact mechanism of interference is not yet specifically defined, it is likely caused by lack of enzyme specificity, due to the similarity in structure between glucose and other sugars, such as maltose and galactose (Figure 2) .
Enteral feeds, such as Peptamen, introduce oligosaccharides, such as maltodextrin, into the gastrointestinal (GI) tract. Maltodextrin is a sweet polysaccharide that is used to provide both thickening to the feed texture and caloric content. Digestion is initiated rapidly in the GI tract by carbohydrate-specific hydrolyases bound to the brush border of the small intestine. Maltodextrin is generally not absorbed whole, but instead is digested to monosaccharide components prior to transport across the surface membrane of the intestinal epithelial cells.
Under normal circumstances, disaccharides do not passively cross the intestinal barrier. Sucrose, a disaccharide of glucose and fructose, is not absorbed through the mucosa of an intact GI tract, but may be absorbed in the presence of barrier breakdown, such as ulcers, inflammation and atrophic gastritis [10, 11] . It is presumed that as with sucrose, maltodextrin-or a smaller oligosaccharide metabolite or maltose-may be absorbed by passive diffusion in the setting of gastric inflammation.
Interestingly, nonglucose sugars may stimulate endogenous insulin release. When given by intravenous infusion to dogs, xylitol, a 5-carbon sugar alcohol, resulted in measurable increases in insulin secretion [12] . This presumably occurs as a result of structural similarity between xylitol and glucose. Although endogenous insulin levels were not measured on our patient, the hypoglycemia in this case was likely to have occurred from the administration of exogenous insulin, administered on the basis of an elevated bedside glucometer reading.
Additionally, it is possible that the feeding solutions were a contaminant on the patientís hand and resulted in external interference rather than reflecting absorption. However, this is unlikely, as skin is routinely cleaned with alcohol swabs prior to glucose testing and due to the consistent finding on repetitive analyses.
CONCLUSION
As with other nonglucose sugars, false elevation of blood glucose measured on certain point-of-care glucometers can occur following the oral administration of maltodextrin. Further studies should evaluate the likelihood of this problem based on the specific glucometer type used for the measurement.
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